Eric Topol, JAMA, and Martha Gulati point to VESALIUS-CV: evolocumab plus statin reduced first major cardiovascular events in high-risk patients with diabetes without known significant atherosclerosis, suggesting broader primary-prevention use.
In a randomized trial of a PCSK9 inhibitor [for LDL cholesterol lowering] vs placebo for patients with diabetes and no known heart disease, there was significant reduction of major cardiovascular events including deaths
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial.
Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.
#VESALIUS-CV evaluates evolocumab in patients without established ASCVD.
“Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial.”
“Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.”
“PCSK9 inhibitors transformed secondary prevention— but what about primary prevention?”
significant reduction of major cardiovascular events including deaths
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event
Could this expand who we treat—and when?
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare